Search Results

Typenex® Medical LLC, a pioneer in patient identification solutions, has been awarded a three-year group purchasing contract with Premier, Inc., a leading healthcare improvement company.

Broadcast across the United States brings attention to the under-addressed risk of medication degradation caused by heat exposure and the real-world need for better medication protection and tracking

Typenex® Medical LLC has been awarded a three-year group purchasing agreement for Capital Equipment and Manual Microbiology with Premier.

• Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026 • Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval Program • Commercialization and reimbursement preparations well underway for the U.S., U.K., and Europe in parallel with ongoing partnership discussions